Open letter to Richard Horton (editor of The Lancet) regarding X:BOT Clinical Trial
| Autor: | Dasgupta, Nabarun |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| DOI: | 10.17615/hnr3-de21 |
| Popis: | We write to express concerns regarding the statistical analysis in the X:BOT study published by Lee et al. (2018), and to request that The Lancet correct misstatements about overdose risk with extended-release naltrexone arising from a data error in the original article. Reanalysis of public trial data from NIH shows that the authors of the 2018 publication failed to include multiple overdoses in their comparison of buprenorphine and naltrexone for opioid dependence. This error resulted in the erroneous conclusion that buprenorphine and naltrexone have no difference in overdose risk: The overdose risk among subjects in the naltrexone arm was in fact 2.4 times higher than buprenorphine. The Lancet was notified in February 2022 of this data error but as of October the journal has not issued a Notice of Concern or retraction of the original article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|